These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37537015)

  • 41. Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Feng M; Yang Y; Liao W; Li Q
    Clin Breast Cancer; 2022 Jul; 22(5):e629-e635. PubMed ID: 35418312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
    Berrios K; Burum A; Jeong E; Zhong L
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
    Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
    J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
    [No Abstract]   [Full Text] [Related]  

  • 45. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
    Millar JA; Millward MJ
    Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China.
    Zhang H; Zhang Y; Huang C; Wang J
    Clin Drug Investig; 2021 Jun; 41(6):569-577. PubMed ID: 33876415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
    Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
    Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Shi D; Li Y; Liang X; Chen L
    Front Oncol; 2023; 13():1162360. PubMed ID: 37251935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
    Leung W; Kvizhinadze G; Nair N; Blakely T
    PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.
    Ansaripour A; Uyl-de Groot CA; Redekop WK
    Pharmacoeconomics; 2018 Jan; 36(1):91-103. PubMed ID: 28795341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
    N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
    Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
    Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
    Leung HWC; Chan ALF; Muo CH; Leung JH
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):207-213. PubMed ID: 28965422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial.
    Shiroiwa T; Fukuda T; Shimozuma K
    Br J Cancer; 2011 Oct; 105(9):1273-8. PubMed ID: 21959871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Huang X; Lin S; Rao X; Zeng D; Wang H; Weng X; Huang P
    Clin Breast Cancer; 2021 Aug; 21(4):e479-e488. PubMed ID: 33676870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.